Overview

Brilinta Taiwan Post Approval Safety Study

Status:
Completed
Trial end date:
2017-02-09
Target enrollment:
Participant gender:
Summary
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Ticagrelor